Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once‐daily, all oral, ribavirin (RBV)‐free, direct‐acting antiviral regimen, was evaluated for safety and efficacy in hepatitis C virus genotype 2 (GT2)–infected Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyoda, Hidenori, Chayama, Kazuaki, Suzuki, Fumitaka, Sato, Ken, Atarashi, Tomofumi, Watanabe, Tsunamasa, Atsukawa, Masanori, Naganuma, Atsushi, Notsumata, Kazuo, Osaki, Yukio, Nakamuta, Makoto, Takaguchi, Koichi, Saito, Satoru, Kato, Koji, Pugatch, David, Burroughs, Margaret, Redman, Rebecca, Alves, Katia, Pilot‐Matias, Tami J., Oberoi, Rajneet K., Fu, Bo, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814891/
https://www.ncbi.nlm.nih.gov/pubmed/28865152
http://dx.doi.org/10.1002/hep.29510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814891/
https://www.ncbi.nlm.nih.gov/pubmed/28865152
http://dx.doi.org/10.1002/hep.29510

Ejemplares similares